Pharmafile Logo
Pharmafocus logo
Advanced Search

sirukumab

Showing 5 posts of 5 posts found.

jj_2johnson_and_johnson

FDA rejects J&J’s treatment for rheumatoid arthritis

September 25, 2017
Sales and Marketing Johnson & Johnson, biotech, drugs, pharma, pharmaceutical, sirukumab

Perhaps unsurprisingly, after the FDA’s advisory committee had voted 12-1 against approval of Johnson & Johnson’s drug, the FDA returned …

News
janssen_latest_logo_on_sign

FDA turns down Janssen’s sirukumab for rheumatoid arthritis

August 3, 2017
Sales and Marketing FDA, Janssen, drugs, life sciences, medicine, pharma, pharmaceuticals, rheumatoid arthritis, sirukumab

Janssen has announced that it has suffered a knockback to its plans to commercialise sirukumab in the US in the …

News
clinical_trial

GSK/J&J release how their drug measures up against Humira

November 18, 2016
Medical Communications, Research and Development GSK, Humira, Janssen, Johnson & Johnson, sirukumab

GlaxoSmithKline and Janssen, part of Johnson & Johnson, released the results of their two Phase III trials exploring treatment options …

News
gsk_hq_close

GSK and J&J file rheumatoid arthritis treatment sirukumab in EU

September 13, 2016
Manufacturing and Production, Sales and Marketing GSK, GlaxoSmithKline, Johnson & Johnson, rheumatoid arthritis, sarilumab, sirukumab

GlaxoSmithKline and partner Johnson & Johnson’s Janssen Biologics unit have filed for approval of rheumatoid arthritis (RA) treatment sirukumab in …

News
lab

GSK, Janssen RA treatment meets co-primary endpoints in Phase III trial

June 9, 2016
Research and Development GSK, Janssen, eular 2016, rheumatoid arthritis, sirukumab

GSK (LSE: GSK) and Janssen, a division of Johnson and Johnson, have announced data from a pivotal Phase III study …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024